Riluzole

證據等級: L5

預測適應症: 10 個

Riluzole: ALS Treatment — No TxGNN Repurposing Prediction Available

One-Sentence Summary

Riluzole is an established treatment for Amyotrophic Lateral Sclerosis (ALS), acting as a glutamate release inhibitor with neuroprotective properties. However, this Evidence Pack contains no TxGNN prediction data and no predicted indications, making it impossible to conduct a full repurposing evaluation at this time. Multiple blocking data gaps — including missing original indication records, MOA data, and safety information — must be resolved before this assessment can proceed.

Quick Overview

Item	Content
Original Indication	Not populated in this Evidence Pack (general knowledge: ALS / Motor Neurone Disease)
Predicted New Indication	Not available — `predicted_indications` array is empty
TxGNN Prediction Score	N/A
Evidence Level	Cannot be determined
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why Prediction Data Is Unavailable

The Evidence Pack for Riluzole (DrugBank: DB00740) was generated with significant data gaps. Specifically:

predicted_indications is an empty array — the TxGNN pipeline either did not run for this candidate or returned zero predictions.
original_indications is also an empty array — the TFDA query returned 0 results, which is consistent with the drug being not marketed in Taiwan/Germany.
original_moa is flagged as [Data Gap] — the DrugBank query logged a successful retrieval (result_count: 1) but no MOA was mapped into the output schema.

From general pharmacological knowledge: Riluzole (Rilutek®) is approved in the EU and US for ALS/MND. Its mechanism involves inhibition of presynaptic glutamate release and blockade of voltage-gated sodium channels, reducing excitotoxic neuronal damage. This context is provided for background only and does not substitute for a properly populated Evidence Pack.

Currently, detailed mechanism of action data is not available in this pack. Based on known information, Riluzole belongs to the benzothiazole class and its efficacy in ALS has been proven clinically; a properly populated MOA field would be needed to assess mechanistic applicability to any new indication.

Germany Market Information

No authorisations found. Riluzole has 0 registered licenses in the queried market. This section cannot be populated.

Safety Considerations

Please refer to the package insert for safety information.

(All safety fields — key warnings, contraindications, and DDI — returned [Data Gap] or not_found. The TFDA package insert query did log a success (result_count: 1), suggesting source data exists but was not parsed into the Evidence Pack schema.)

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is structurally incomplete — no TxGNN predicted indications, no original indication records, no MOA, and no safety data — making any repurposing evaluation premature and potentially misleading.

To proceed, the following is needed:

Priority	Gap ID	Item	Action Required
🔴 Blocking	DG001	TFDA/BfArM package insert warnings & contraindications	Parse the already-retrieved PDF (query log ID 4, `result_count: 1`) into the safety schema
🔴 Blocking	—	`predicted_indications` is empty	Re-run TxGNN prediction pipeline for DB00740; verify input node mapping
🟠 High	DG002	MOA (mechanism of action)	DrugBank returned a result (query log ID 3, `result_count: 1`); extract `mechanism_of_action` field from API response
🟠 High	—	`original_indications`	Riluzole is not marketed in Taiwan/Germany — source EU SmPC from EMA or FDA label to populate this field
🟡 Medium	—	DDI data	Expand DDI query to DrugBank or credible interaction database; current result is `not_found`

Once these gaps are resolved and TxGNN produces at least one scored indication, this report should be regenerated using Evidence Pack v5+.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.